GORASP2 and cancer: This implies that a genetic deletion or mutation of GRASP55 in cancer might lead to an enhanced glycoenzyme recycling, increasing their levels by subtracting them from the normal lysosomal leakage and conferring a positional advantage in competition reactions, thereby affecting the glycosylation metabolic flux.